Milestone Pharmaceuticals
MIST
87 hedge funds and large institutions have $47.2M invested in Milestone Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 14 closing their positions.
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
9% more funds holding
Funds holding: 80 → 87 (+7)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7.49% less ownership
Funds ownership: 41.09% → 33.59% (-7.5%)
33% less capital invested
Capital invested by funds: $70.7M → $47.2M (-$23.5M)
41% less call options, than puts
Call options by funds: $426K | Put options by funds: $718K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$6.7M |
| 2 |
Goldman Sachs
New York
|
+$3.5M |
| 3 |
Millennium Management
New York
|
+$2M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.49M |
| 5 |
Two Sigma Investments
New York
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.68M |
| 2 |
Pathstone Holdings
Englewood,
New Jersey
|
-$1.75M |
| 3 |
Jane Street
New York
|
-$1.63M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.34M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$455K |
MIST Hedge Fund Activity: Q1 2026 in Review
87 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q1 2026, worth a combined $47.2M — down 33% from $70.7M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MIST positions and 14 closed out — a net gain of 7 holders — while 23 added to existing stakes and 19 trimmed.
The largest buyer was RTW Investments, adding an estimated $6.7M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $5.68M sold.
- 87 institutional investors held Milestone Pharmaceuticals (MIST) as of Q1 2026, up from 80 in Q4 2025.
- Funds reported $47.2M of Milestone Pharmaceuticals stock for Q1 2026, down 33% quarter-over-quarter.
- 21 funds opened new Milestone Pharmaceuticals positions in Q1 2026 and 14 closed out, a net change of +7 holders.
- The largest Milestone Pharmaceuticals buyer in Q1 2026 was RTW Investments, an estimated $6.7M added.
- The largest Milestone Pharmaceuticals seller in Q1 2026 was Adage Capital Partners, an estimated $5.68M sold.
Based on aggregated 13F filings for Q1 2026.